Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia.
Due to toxic side effects of aluminum-containing agents for treatment of uremic hypophosphatemia, much interest has been focused upon aluminum-free phosphate binder alternatives. From results of experimental studies with calcium acetate, this salt has been suggested as a possible effective and safe phosphate binder. In the present study, calcium acetate was used during a mean of 11 months for serum phosphate control in 30 uremic patients previously treated with aluminum and/or calcium carbonate. Satisfactory control of serum phosphate was achieved during the study (mean phosphate concentration +/- SE: 2.15 +/- 0.12 mmol/l compared to prestudy 2.23 +/- 0.19 mmol/l). Mean serum concentrations of calcium, alkaline phosphatase and parathyroid hormone did not change significantly during the study. Serum aluminum decreased significantly (p less than 0.01). Moderate hypercalcemia was observed in 6 patients. Calcium acetate treatment was withdrawn in 2 patients due to gastrointestinal discomfort. It is concluded that calcium acetate seems to be an effective phosphate binder alternative with relatively few side effects.
Department of Medicine, University Hospital, Uppsala, Sweden.
B
B
Wikström
B G
BG
Danielson
B
B
Fellström
D000085:Acetates / Q000627:therapeutic use*; D019342:Acetic Acid; D000293:Adolescent; D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000535:Aluminum / Q000097:blood; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood*; D014511:Uremia / Q000097:blood*
D000085:Acetates; D010281:Parathyroid Hormone; D010710:Phosphates; D000536:Aluminum Hydroxide; D000535:Aluminum; D000469:Alkaline Phosphatase; D002119:Calcium Carbonate; D019342:Acetic Acid